Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.37 |
| ▸ | CCR9 | P51686 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 4/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579634 | 0.88 | SERPINE1 (0.40) | CCR9KDM4EALDH1A1GLAGAA | |
| SCHEMBL1397638 | 0.88 | HCRTR1 (0.37) | HCRTR1HCRTR2CCR9 | |
| SCHEMBL1397562 | 0.87 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL1397554 | 0.84 | CCR9 (0.38) | CCR9KDM4EALDH1A1GLAGAA | |
| SCHEMBL3575555 | 0.84 | F10 (0.42) | HCRTR1HCRTR2CCR9F10SERPINE1 | |
| SCHEMBL3576868 | 0.83 | HCRTR1 (0.42) | HCRTR1HCRTR2CCR9F10SERPINE1 | |
| SCHEMBL3583634 | 0.81 | SERPINE1 (0.39) | CCR9KDM4EALDH1A1GLAGAA | |
| SCHEMBL3584396 | 0.80 | C5AR1 (0.44) | CCR9KDM4EALDH1A1GLAGAA | |
| SCHEMBL3574044 | 0.80 | NR1H4 (0.37) | CCR9 | |
| SCHEMBL3581193 | 0.80 | CCR9 (0.39) | CCR9KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007726-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7674815-B2 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2007726-A2 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007090749-A2 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | CYP2C19, CYP2C9, CYP3A43 | HCRTR1 3669/4885HCRTR2 3272/4885CCR9 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.